📇 Rhumatologue · PESSAC CEDEX · (33) · Hospitalier

M FRANCOIS TISON

Pourquoi vous devez consulter ce praticien

5 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (4 thèses dirigées)
Expérience confirmée
36 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
144.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PESSAC CEDEX (33)HospitalierRPPS 10002812468

EnseignementExpérience confirmée

36ans d'exercice (thèse 1990)

📊 Reconnaissance scientifique : 63/100📝 252 articles publiés🇫🇷 Publications académiques françaises (8)🎓 4 thèses dirigées

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

Progress in neurobiology · 2015

📚 378 citations🎯 RCR 15.96Top 1% NIH🔓 Open Access

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Movement disorders : official journal of the Movement Disorder Society · 2016

📚 114 citations🎯 RCR 4.87Top 8% NIH🩺 Clinique

Lire l'abstract Crossref ↓

ABSTRACT Background The metabotropic glutamate receptor 5‐negative allosteric modulator dipraglurant reduces levodopa‐induced dyskinesia in the MPTP‐macaque model. The objective of this study was to assess the safety, tolerability (primary objective), and efficacy (secondary objective) of dipraglurant on levodopa‐induced dyskinesia in Parkinson's disease (PD). Methods The study was a phase 2A double‐blind, placebo‐controlled, randomized (2:1), 4‐week, parallel‐group, multicenter dose‐escalation (from 50 mg once daily to 100 mg 3 times daily) clinical trial involving 76 PD subjects with moderate to severe levodopa‐induced dyskinesia. Safety and tolerability were assessed based on clinical and biological examination and adverse events recording. Secondary efficacy outcome measures included the modified Abnormal Involuntary Movement Scale, UPDRS, and diaries. Pharmacokinetics were measured at 3 visits following a single dose. Results Fifty‐two patients were exposed to dipraglurant and 24 to placebo. There were no major safety concerns. Two subjects did not complete the study because of adverse events. Most frequent adverse events included dyskinesia, dizziness, nausea, and fatigue. Dipraglurant significantly reduced peak dose dyskinesia (modified Abnormal Involuntary Movement Scale) on day 1 (50 mg, 20%; P = 0.04) and on day 14 (100 mg, 32%; P =0 .04) and across a 3‐hour postdose period on day 14 ( P = 0.04). There was no evidence of worsening of parkinsonism. Dipraglurant was rapidly absorbed (t max = 1 hour). The 100‐mg dose led to a mean C max of 1844 ng/mL on day 28. Conclusions Dipraglurant proved to be safe and well tolerated in its first administration to PD patients. Its efficacy in reversing levodopa‐induced dyskinesia warrants further investigations in a larger number of patients. © 2016 International Parkinson and Movement Disorder Society

Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment

Neurology · 2019

📚 79 citations🎯 RCR 5.14Top 7% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M FRANCOIS TISON

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (36) — classées par pathologie

Transversal19

Épidémiologie & registres3

Essai clinique3

Génétique3

Recommandations2

Santé mentale / fatigue2

Biomarqueurs / Auto-Ac1

Pharmacovigilance1

Qualité de vie / PROMs1

Revue générale1

Partager cette fiche